Flynn Management LLC, its general partner
@Deerfield Management Company, L.p. (series C)
Latest period2024 - Q3ReportedManaged Assets$6.693BTotal holdings443
Assets growth rate11.36%Assets growth rate (2-Q avg)7.96%Continuous growth in asset value4 quarters
Portfolio positions
This chart displays the top 10 holdings in Deerfield Management Company, L.p. (series C)'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 443 positions.
Assets under management
The assets under management (AUM) of Deerfield Management Company, L.p. (series C) over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.693B in assets, with a quarterly growth rate of 11.36% and a 2-quarter average growth rate of 7.96%. The portfolio is managed by Flynn Management LLC, its general partner, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
TXG10x Genomics Inc
| 0.51% | $34.072M 1.509M shares@ $22.59 avg price | Increased 152.76% |
CGONCg Oncology Inc
| 0.48% | $32.097M 850,695 shares@ $37.73 avg price | Increased 96.23% |
DCGODocgo Inc
| 0.45% | $30.1M 9.066M shares@ $3.32 avg price | Increased 25.99% |
FHTXFoghorn Therapeutics Inc
| 0.43% | $28.19M 3.028M shares@ $9.32 avg price | Increased 20.23% |
INMDInmode Ltd
| 0.4% | $26.759M 1.579M shares@ $16.96 avg price | Increased 35.32% |
NAMSNewamsterdam Pharma Company
| 0.23% | $14.969M 901,750 shares@ $16.6 avg price | Increased 3.74% |
VTYXVentyx Biosciences Inc
| 0.22% | $14.64M 6.716M shares@ $2.18 avg price | Increased 15.2% |
PHRPhreesia Inc
| 0.19% | $12.408M 544,448 shares@ $22.8 avg price | Increased 183.06% |
INSMInsmed Inc
| 0.06% | $3.859M 52,861 shares@ $73.0 avg price | Increased 365.37% |
MLABMesa Labs Inc
| 0.04% | $2.554M 19,664 shares@ $129.86 avg price | Increased 449.13% |